Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Allecra Therapeutics GmbH

https://allecra.com/

Latest From Allecra Therapeutics GmbH

Concizumab, Elranatamab & Talquetamab Among New EU Filings At EMA

The European Medicines Agency has started reviewing a new batch of medicines for potential pan-EU marketing approval.

Europe Approvals

Allecra Seeks US Partnership For Urinary Tract Asset As Regulatory Filings Approach

The French firm is searching for a US partner with strong foundations in the hospital sector after securing EU and China deals for its complicated urinary tract infection candidate that combines cefepime and enmetazobactam, which is nearing regulatory submission in key markets.

Deals Infectious Diseases

Deal Watch: How Did J.P. Morgan Deal-Making Compare To Prior Years?

Licensing deals and partnerships carried the day during another hectic J.P. Morgan Healthcare Conference. Pfizer racked up its third deal of the week in a cancer collaboration with Dren Bio.

Deal Watch Business Strategies

Pipeline Watch: Phase III Starts With Murepavadin, CSL112 And Vibegron

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
UsernamePublicRestriction

Register